Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.

Interactions of oestradiol benzoate and promegestone upon basal and trh‐induced prolactin secretion in postmenopausal women

Abstract: The interactions of ovarian steroids with PRL secretion in women are still controversial Ten healthy postmenopausal women, on no medication, received during the first period of 2 months later in a cross-over design study, im injections of 0625 mg of oestradiol benzoate (EB) alone for 10 d or in combination with 750 micrograms/d of a pure progestin promegestone for 10 d A TRH (200 micrograms iv) stimulation test was performed before the start and at the completion of each treatment period Basal plasma gonadotrophins, PRL and oestradiol were measured every day by radioimmunoassay The EB-induced rise in oestradiol levels was similar during the two periods In response to EB treatment serum PRL levels increased from 61 +/- 09 ng/ml to 229 +/- 34 ng/ml With the addition of promegestone, the increase in PRL, from 67 +/- 13 ng/ml to 138 +/- 25 ng/ml, was significantly diminished (P less than 0001) The PRL release induced by TRH was significantly greater with EB treatment than was the response with the combined treatment (P less than 005, Wilcoxon test to compare the areas under the curves) These data suggest that in postmenopausal women oestrogens act as stimulators of PRL release and promegestone is able to partially counteract the stimulatory effect of oestradiol benzoate upon basal and TRH-stimulated PRL secretion

A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

Abstract: A total of 29 patients with advanced malignancy were treated with recombinant interferon gamma (rIFN gamma, specific activity = 2.10(7) units/mg, purity greater than 95%) given by intravenous bolus at doses escalating from 0.01 mg/m2 to 5 mg/m2 (2 x 10(5) - 10(8) IU/m2) in nine successive steps (at least 3 patients/step). Injections of rIFN gamma were repeated every 72 h for 15 days. Toxicity was evaluated according to the WHO scale. Fever and chills occurred in all patients treated without clear dose effect. Nausea and vomiting appeared at the fifth dose level and their frequency seemed to be dose-related. Cardiovascular side-effects (first-degree atrioventricular reversible block) were observed at the 2 mg/m2 and 5 mg/m2 levels (3 patients). Hematological toxicities were mild (2 grade 1 and 1 grade II cases of granulocytopenia). Minor biological modifications included a transitory rise in hepatic enzymes (12 patients), which correlated with the presence of liver metastasis. Hypocholesterolemia was observed in 18 patients. The appearance of antibodies against rIFN gamma was not detected. One partial clinical response was observed in a patient receiving 2 mg/m2. During rIFN gamma therapy this patient had the highest scores in this series for peripheral T lymphocytes with an activated phenotype (HLA DR+, TAC+) = 15% and for natural killer (NK) cells (NKH1, Leu19+) = 17%. rIFN gamma appears as a well-tolerated and promising therapeutic agent with toxicities and mode of action probably distinct from IFN alpha and beta.